Connor, Clark & Lunn Investment Management (CC&L)’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-213,865	Closed	-$1.43M	–	1613
2023 Q3	$1.43M	Sell	213,865 -56,413	-21%	-$469K	0.01%	708
2023 Q2	$2.45M	Buy	270,278 +203,621	+305%	+$1.8M	0.01%	563
2023 Q1	$485K	Buy	+66,657	New	+$494K	﹤0.01%	892

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PNT Position: Q4 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 213,865 shares — an estimated $1.43M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PNT in Q1 2023 and held it in 3 quarters. The position peaked at $2.45M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 213,865 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $1.43M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2023 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s POINT Biopharma Global Inc. Common Stock position peaked at $2.45M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2023, filed 9 Feb 2024.